August 22, 2024
“Deutsche Bank has reached settlements with nearly 60% of plaintiffs in a long-running case alleging the German lender underpaid for its acquisition of Postbank more than a decade ago. The German lender said the settlement would allow it to release… Continue Reading…
August 22, 2024
“…The company’s shares rose more than 15% in morning trading. Here’s how the Bike and Tread maker performed compared with what Wall Street was anticipating, based on a survey of analysts by LSEG: For the three-month period that ended June… Continue Reading…
August 14, 2024
“…Here’s how the company did compared with what Wall Street was expecting, based on a survey of analysts by LSEG: The company said gross merchandise volume, or the total volume of merchandise sold on the platform, jumped 22% during the… Continue Reading…
August 6, 2024
“…Here’s how Apple did versus LSEG consensus estimates for the quarter ended June 29: Apple expects similar overall revenue growth in the current quarter, company finance chief Luca Maestri said on a call with analysts…” https://www.cnbc.com/2024/08/01/apple-aapl-earnings-report-q3-2024.html
August 1, 2024
“Headline inflation in the euro zone unexpectedly rose to 2.6% in July, the European Union’s statistics agency said Wednesday. Core inflation, which excludes more volatile energy, food, alcohol and tobacco prices, hit 2.9% in July, which was higher than expected.… Continue Reading…
July 2, 2024
“ Share prices of Cirrus Logic (NASDAQ: CRUS) have been in fine form so far in 2024, clocking gains of 48% as Wall Street turns bullish on the chipmaker’s prospects. The market is excited about a turnaround in the smartphone market, its solid… Continue Reading…
June 6, 2024
“…Just six large tech stocks contributed to more than 75% of the S&P 500’s gain in May, a move reminiscent of how the “Magnificent Seven” tech stocks drove the market rally in 2023. Rises in Apple (AAPL), Alphabet (GOOGL, GOOG), Microsoft (MSFT),… Continue Reading…
March 29, 2024
“Shares of Viking Therapeutics (NASDAQ: VKTX) are up about 275% in 2023, but analysts on Wall Street think it isn’t finished climbing yet. The consensus price target on the clinical-stage biotech stock suggests a 47% gain could be up ahead…. Shares of Iovance Biotherapeutics (NASDAQ: IOVA) have more… Continue Reading…
Recent Comments